Antibiotic-Associated Diarrhea Treatment Market Trends and Forecast
The future of the global antibiotic-associated diarrhea treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, drug store, and online pharmacy markets. The global antibiotic-associated diarrhea treatment market is expected to grow with a CAGR of 11.5% from 2025 to 2031. The major drivers for this market are the increasing use of antibiotics, the rising awareness of gut health, and the growing prevalence of gastrointestinal disorders.
• Lucintel forecasts that, within the route of administration category, oral is expected to witness higher growth over the forecast period.
• Within the distribution channel category, online pharmacy is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Antibiotic-Associated Diarrhea Treatment Market
The market for the antibiotic-associated diarrhea treatment is now witnessing a dramatic paradigm shift from the traditional symptomatic treatment to more advanced, targeted, and preemptive strategies. The shift is fueled by growing fears of antibiotic resistance, increased knowledge of the role of the gut microbiota in health and disease, and the ongoing problem of recurrent Chloridoids difficile infection (CDI). New trends signal a worldwide commitment to enhancing patient outcomes, minimizing healthcare burdens, and encouraging a more integrated approach towards gastrointestinal health in the setting of antibiotic therapy.
• Microbiome-Based Therapies: This trend involves treatments aimed at restoring or modulating the gut microbiome, which is altered by antibiotic treatment and contributes to AAD. This entails the expanding use of probiotics, especially multi-strain products with established efficacy, and the accelerating growth of fecal microbiota transplantation (FMT) and orally delivered live biotherapeutic agents. The effect is widespread, from mere killing of pathogens to restoring a healthy microbiome balance, thus decreasing AAD incidence and recurrence, most importantly in severe infections such as C. difficile infection.
• Targeted Novel Antibiotics: With increasing antibiotic resistance, there is a greater push toward the creation of narrow-spectrum antibiotics that are specifically directed toward pathogenic bacteria, for example, Chloridoids difficile, with less disruption to beneficial gut flora. The newer agents seek to enhance efficacy, diminish collateral damage to the microbiome, and reduce recurrence rates of AAD and CDI. Their value is to provide more effective and safer therapies, having the potential to overcome resistance problems that older, broad-spectrum antibiotics may create, and to generate improved patient outcomes with fewer side effects.
• Diagnostic Advances: Better and faster diagnostic methods are becoming available for identifying the specific pathogens responsible for AAD, especially chloridoids difficile. These innovations, such as molecular tests and improved enzyme immunoassays, enable faster and more accurate diagnosis, which translates to timely and proper treatment. The effect is substantial, as early and accurate diagnosis will avoid disease progression, decrease the transmission of infection, maximize antibiotic stewardship by directing targeted therapy, and ultimately enhance patient management, resulting in improved clinical outcomes.
• Prophylactic Probiotics and Preventive Strategies: One emerging trend is the proactive utilization of certain probiotic strains for preventing AAD among patients undergoing antibiotics. Clinical guidelines are increasingly coming to appreciate the protective role of certain probiotics against AAD, especially in high-risk individuals. This move towards prevention is intended to decrease the overall incidence of AAD, minimize patient discomfort, and lower healthcare expenditure on treating the condition. The effects are observed in a more proactive care of the patient, which might lighten the healthcare systemÄX%$%Xs burden.
• Telemedicine and Remote Patient Monitoring: The combination of telemedicine and remote monitoring solutions is becoming a trend in AAD management, especially for patient follow-up and monitoring, especially recurrent CDI. Telemedicine consultations can enable on-time evaluation of symptoms, compliance with treatment protocols, and overall patient care, particularly for patients who are not able to attend healthcare centers on a regular basis. This trend enhances care accessibility, improves patient convenience, and enables more effective management of AAD, especially in recurrent or chronic conditions.
These new trends are essentially redefining the antibiotic-associated diarrhea treatment market by enabling more accurate, preventive, and patient-focused care. The focus on microbiome rehabilitation, directed therapies, and sophisticated diagnosis is redefining treatment paradigms, resulting in enhanced efficacy and fewer recurrences. In addition, the incorporation of digital healthcare solutions is improving accessibility and control. This holistic development is broadening the market with innovative products, promoting personalized treatment strategies, and ultimately enhancing the quality of life in patients suffering from AAD.
Recent Development in the Antibiotic-Associated Diarrhea Treatment Market
The market for antibiotic-associated diarrhea treatment has seen substantial recent growth, fueled by an increased understanding of the gut microbiome, the ongoing threat of antimicrobial resistance, and an increasing focus on patient-centered treatment. These developments are revolutionizing the diagnosis, management, and prevention of AAD, especially chloridoids difficile infection (CDI). From new therapeutic drugs to emerging diagnostic technologies and a revival of interest in gut health, these advances seek to enhance patient outcomes, minimize disease recurrence, and offset the wider ramifications of antibiotic usage on the human microbiome.
• Microbiome-Modulating Therapies Emergence: A major milestone is the expanded access and acceptance of microbiome-modulating therapies, primarily fecal microbiota transplantation (FMT) for recurrent chloridoids difficile infection (CDI), and the development of orally taken live biotherapeutic products. These therapies have the mechanism of restoring a healthy equilibrium of gut bacteria, specifically addressing the antibiotic-induced dysbiosis. This progress plays a major role in the market by providing very effective treatment possibilities for patients that are not treated using traditional antibiotics and by decreasing the high re-infection rates of CDI, thereby enhancing long-term patient well-being.
• Approval and Use of New Antibiotics for CDI: The market has witnessed the approval and increasing use of new targeted antibiotics specifically for chloridoids difficile infection, e.g., fidaxomicin. These antibiotics are superior to traditional broad-spectrum agents by exerting a more selective effect on C. difficile, preserving to the greatest extent possible beneficial flora of the intestine, and revealing lower recurrence rates. This advance offers clinicians improved weapons against resistant C. difficile infection and provides patients with improved outcomes, lessening the impact of recurrent infection and hospitalization.
• Progress toward Rapid Diagnostic Tests for CDI: Important progress has been reported in creating rapid and reliable diagnostic tests for chloridoids difficile infection. Molecular tests, including PCR assays and improved enzyme immunoassays, now enable more rapid and sensitive detection of the bacterium and its toxins. This is important because early detection and accurate diagnosis make early intervention possible, enabling clinicians to begin correct treatment earlier. This eventually results in better patient control, avoids disease progression, and facilitates more effective infection control measures, lessening overall transmission.
• Expanded Research and Development of Probiotics: There has been a dramatic rise in research and development activities aimed at the discovery and validation of certain probiotic strains for the prevention and treatment of AAD. This encompasses research on multi-strain compositions and their modes of action. The effect is increasing evidence favoring the prophylactic administration of specific probiotics in decreasing AAD risk in populations at high risk. This trend is moving toward more specific and evidence-driven recommendations for the use of probiotics beyond mere promotion of gut health to being an accepted medical therapy for AAD.
• Emphasis on Antimicrobial Stewardship Programs: Healthcare organizations globally are increasingly adopting and expanding antimicrobial stewardship programs, which indirectly but significantly influence the AAD market. Such programs aim to optimize antibiotic use, minimize unnecessary antibiotic usage, and encourage appropriate drug choice and course. This trend results in a reduction of total antibiotic use, consequently lowering the rate of AAD. Through reducing the source of AAD, stewardship programs provide a healthier patient base and reduce strain on the AAD treatment market over the long term.
These new advances are having a deep influence on the antibiotic-associated diarrhea treatment market by moving the focus from reactive care to proactive prevention and pinpoint interventions. Microbiome therapies and new antibiotics provide more potent solutions for difficult cases, better diagnostics and probiotic research improve early management and prevention, and altogether, these advances are resulting in improved patient outcomes, lower rates of recurrence, and more sustainable management of the aftermath of antibiotic therapy.
Strategic Growth Opportunities in the Antibiotic-Associated Diarrhea Treatment Market
The antibiotic-associated diarrhea treatment market offers many strategic opportunities for growth across a range of applications, driven by an increasing requirement for efficient prevention, management, and recurrence prevention. As knowledge about the gut microbiome is enriched and antimicrobial resistance is ever-increasing, refined applications for AAD therapies are arising as key investment and innovation arenas. Characterizing and capitalizing on such unique opportunities will allow firms to target particular patient groups and healthcare environments, ultimately optimizing market penetration and fulfilling unmet medical needs in a critical area.
• Management of Hospital-Acquired Infections: Hospitals are a notable opportunity for growth because of the frequent occurrence of chloridoids difficile infection (CDI), a serious type of AAD, within healthcare environments. Strategic development in this case means creating and distributing therapies, diagnostics, and preventives targeted specifically for high-risk hospitalized patients. Examples are new antibiotics, rapid diagnostic tests to catch the disease early, and preventive probiotics integrated into hospital practice. The effect is decreased healthcare-associated infections, reduced patient morbidity and mortality, reduced healthcare expenses, and better hospital quality statistics.
• Recurrent Chloridoids difficile Infection Therapy: The high rate of CDI recurrence, frequently compounded by repetitive courses of antibiotics, presents a significant growth area for specialist treatments. This segment addresses treatments intended to stop the cycle of recurrence, including fecal microbiota transplantation (FMT) and recently approved orally dosed live biotherapeutic products. Firms designing these sophisticated, non-antibiotic therapies can take a large proportion of this difficult patient population, representing a revolutionary effect through radically curbing recurrence and enhancing patient quality of life.
• Pediatric AAD Prophylaxis and Treatment: The pediatric patient population is especially susceptible to AAD because of their maturing gut microbiome and heavy antibiotic exposure. This represents an opportunity for child-friendly probiotic formulations and directed AAD therapy. Strategic actions could involve tasty liquid or chewable probiotic supplements with supporting evidence in preventing AAD in children. The effect entails protecting the gut health of children, lowering distress and complications of AAD in the vulnerable population, and offering parents and pediatricians useful, safe alternatives.
• Management of Outpatient and Community-Acquired AAD: Most AAD cases are found in outpatient settings or are community-acquired. This opens up a huge market for affordable and effective over-the-counter (OTC) or easily prescribable therapy. Opportunity for growth exists in formulating well-studied probiotic supplements for prevention of AAD and management of mild AAD, as well as simple-to-use diagnostic tools for primary care physicians. The effect is enhanced patient access to treatment, decreased use of broad-spectrum antibiotics, and empowerment of individuals to treat milder AAD effectively, avoiding further progression to more serious diseases.
• Integration into Antimicrobial Stewardship Programs: Working with and complementing antimicrobial stewardship programs (ASPs) in healthcare organizations is a strategic expansion opportunity. Organizations can provide solutions in line with ASP objectives, for example, diagnostics that inform correct antibiotic prescribing or non-antibiotic treatments that lower future antibiotic exposure. The effect is a more prudent application of antibiotics, which, indirectly, decreases AAD incidence, stimulates demand for particular AAD treatments where needed, and makes companies the main stakeholders in the global fight against antimicrobial resistance as well as patient safety.
These strategic opportunities for growth are greatly affecting the market for antibiotic-associated diarrhea treatment by stimulating a move toward more targeted, preventive, and patient-segment-specific solutions. With a greater emphasis on such areas as hospital-acquired infections, recurrent CDI, pediatrics, and community management, and also integration with antimicrobial stewardship, the market is becoming more specialized and holistic. Through this strategic emphasis, the market is seeing increasing innovation, enhanced clinical results, and ultimately market value expansion through the meeting of key needs along the whole continuum of AAD patient care.
Antibiotic-Associated Diarrhea Treatment Market Driver and Challenges
The market for the antibiotic-associated diarrhea treatment is influenced by a multifaceted interplay of several technological, economic, and regulatory drivers. These factors are both strong drivers, driving innovation and adoption, and large hurdles, requiring skillful handling by industry players. The key drivers are the rising incidence of antibiotic-associated gut dysbiosis and chloridoids difficile infection (CDI), expanding awareness of gut microbiome health, and advances in diagnostic and therapeutic technologies. On the contrary, difficulties like antibiotic resistance, exorbitant development expenses for new therapies, and regulatory challenges have significant impacts on market dynamics.
The factors responsible for driving the antibiotic-associated diarrhea treatment market include:
1. Rising Antibiotic Utilization and AAD: The vast and oftentimes growing usage of antibiotics worldwide is the key driver. Although antibiotics are crucial, inappropriate use causes disruption of the normal intestinal flora with resultant AAD, including the more severe forms such as chloridoids difficile infection. The volume of antibiotic prescriptions is directly correlated with the number of cases of AAD and, therefore, with demand for treatment and prevention modalities. This ongoing correlation provides a stable market for AAD treatment as long as antibiotics continue to be an integral part of contemporary medicine.
2. Increasing Prevalence of Chloridoids difficile Infection: CDI, the most severe manifestation of AAD, is a serious and increasing public health issue with high rates of morbidity, mortality, and recurrence. The spreading prevalence of CDI, especially in healthcare facilities and among susceptible populations, is a principal impetus for the creation and implementation of highly effective, targeted therapies. The desperate requirement to fight this contagious pathogen and mitigate its social burden spurs research, regulatory clearance, and demand in the market for niche CDI treatments.
3. Increased Perception of the Role of Gut Microbiome: Enhanced scientific insight and greater public recognition of the gut microbiomeÄX%$%Xs pivotal position in human health are having a profound effect on the marketplace. This realization is fueling interest in treatments that recolonize gut flora balance, including probiotics and fecal microbiota transplantation. Healthcare providers and patients alike are now realizing that treating AAD is not merely a matter of halting diarrhea but also of reconstituting a healthy microbial community, and thus, there is a trend towards microbiome-focused therapeutic strategies.
4. Advances in Diagnostic Technology: Advances in diagnostic technology, especially for rapid and precise tests for chloridoids difficile and other causative agents of AAD, are primary market drivers. The early detection and treatment based on increased speed and accuracy in diagnostics results in improved patient outcomes and lower healthcare costs. The facility to rapidly detect the causative organism enables the clinician to choose the most optimal therapy, reducing empiric antibiotic use and aiding better management of AAD and infection control.
5. Personalized Medicine and Prophylaxis Trend: The increasing trend towards preventive healthcare and personalized medicine is a strong driver. This entails the identification of high-risk patients for AAD and the institution of prophylactic measures, including the use of specific probiotic strains. Individualized interventions grounded on patient-specific risk factors and microbial characteristics can maximize the effectiveness of treatment and avoid AAD development. This strategy is designed to avoid the negative impacts of antibiotics, enhance patient comfort, and minimize both the incidence and severity of AAD.
Challenges in the antibiotic-associated diarrhea treatment market are:
1. Antimicrobial Resistance: The long-term and rising threat of antimicrobial resistance seriously hampers the AAD market. Overuse and inappropriate use of antibiotics drive the emergence of resistant forms of chloridoids difficile and other bacteria, reducing the efficacy of traditional treatments. This requires ongoing research and development of new, non-antibiotic, or highly targeted antibiotic therapies, which is an expensive and time-consuming process, posing a significant barrier to market innovation and the provision of effective solutions.
2. Excessive Research and Development Expenses: The creation of innovative treatments for AAD, especially microbiome-focused remedies or new antibiotics, comes with high research and development expenses. The intricate biological processes, rigorous regulatory approval procedures, and the necessity for extensive clinical trials are factors that lead to these heavy expenses. Such expenses may discourage small firms from entering the marketplace and affect the pricing and availability of new medications, restricting patient access and decelerating the overall market growth, particularly for innovative inventions.
3. Reimbursement Policies and Regulatory Barriers: Traveling through varied and shifting regulatory environments in various nations is often a significant challenge for AAD treatment developers. Securing approvals for new drugs, particularly live biotherapeutic products, is usually a complicated and time-consuming process. Reimbursement policies by health payers may also have a bearing on market access and adoption. Uncertainty about reimbursement pathways or less-than-optimal price decisions may affect the commercial potential of innovative AAD treatments, regardless of their clinical effectiveness.
All in all, the antibiotic-associated diarrhea treatment market is witnessing robust growth underpinned by rising incidences of AAD and CDI, intensified awareness of the gut microbiome, and advances in diagnostics and therapeutic targeting. These forces are compelling the market towards more novel, prophylactic, and individualized measures. Nonetheless, major challenges such as antimicrobial resistance, high research and development expenses, and intricate regulatory and reimbursement schemes pose major obstacles. These problems would need to be tackled by collective action and long-term innovation if the market is to truly reach its potential in enhancing patient care and discovering solutions to this widespread medical condition.
List of Antibiotic-Associated Diarrhea Treatment Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies antibiotic-associated diarrhea treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antibiotic-associated diarrhea treatment companies profiled in this report include-
• Merck & Co
• TECHLAB
• Manav Drugs
• Pfizer
• Aurobindo Pharma
• CutisPharma
• Cosmo Pharmaceuticals
Antibiotic-Associated Diarrhea Treatment Market by Segment
The study includes a forecast for the global antibiotic-associated diarrhea treatment market by route of administration, distribution channel, and region.
Antibiotic-Associated Diarrhea Treatment Market by Route of Administration [Value from 2019 to 2031]:
• Oral
• Injectable
Antibiotic-Associated Diarrhea Treatment Market by Distribution Channel [Value from 2019 to 2031]:
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
Antibiotic-Associated Diarrhea Treatment Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Antibiotic-Associated Diarrhea Treatment Market
The market for antibiotic-associated diarrhea treatment is facing profound change, spearheaded by greater insight into the gut microbiome, increasing antimicrobial resistance, and a trend towards more preventive and targeted therapy. Previously dominated by symptomatic treatment and rehydration, the market now has increased focus on restoring balance to gut flora and addressing the causes of AAD, most notably Chloridoids difficile infection (CDI). This transformation is driving the development of probiotics, new antibiotics, and even fecal microbiota transplantation (FMT), all symbolizing a concerted global push to optimize patient treatment and counter the pervasive effects of antibiotic consumption.
• United States: The United States AAD treatment market is dominated by an intense focus on C. difficile infection, the prevalent issue. Recent advances include the approval and rising use of new antibiotics such as fidaxomicin, with enhanced efficacy and reduced recurrence versus conventional treatments. A large increase in clinical trials and research on microbiome-targeted therapies, including oral live biotherapeutics, for recurrent CDI is also observed. The market is strongly driven by clinical guidelines and reimbursement policies from healthcare, which prefer effective and evidence-based treatments.
• China: The market for AAD treatments in China is growing very fast, driven by a large population and rising use of antibiotics. Traditional antibiotics and probiotics are commonly used, but there is a blossoming interest in more sophisticated treatments. The market is seeing growth in domestic research and development for new probiotics and, to a lesser extent, focused antibiotics. Public education on gut health and the consequences of antibiotics is also on the rise, creating an enhanced need for preventive care and effective treatment of AAD, such as through traditional Chinese medicine practices blended with contemporary therapies.
• Germany: The German AAD treatment economy prioritizes patient safety and evidence-based medicine. Antibiotics for severe infections and confirmed probiotics continue to be the norm, but there is aggressive promotion of antimicrobial stewardship programs aimed at eliminating unnecessary prescriptions, thus preventing AAD incidence. Investigations on newer, non-antibiotic therapies, especially on microbiome-modulating agents, are also becoming more popular. The healthcare system in Germany favors high-quality, effective treatments, which results in the selective uptake of new drugs backed by sound clinical data and cost savings.
• India: India offers a fast-developing but multifaceted AAD treatment market. High antibiotic use, often indiscriminate, supports a considerable AAD and resistance burden. The market reflects extensive usage of low-cost probiotics and conventional antibiotics. Yet, growing awareness among the healthcare community and the public regarding targeted therapy and avoidance of AAD exists. This is creating the scope for generic versions of recently introduced drugs and the innovation of low-cost probiotic products, along with efforts directed toward restraining antibiotic use.
• Japan: The Japanese market for AAD treatment is developed and features a strong focus on clinical performance and patient convenience. Although longstanding antibiotics and probiotics are well entrenched, they are oriented toward minimizing recurrence rates, particularly against C. difficile infection. Research and development are ongoing in the fields of gut microbiome modulation and searching for new therapeutic agents. The Japanese healthcare system encourages the application of therapies with established benefits, and there is also a culture
Features of the Global Antibiotic-Associated Diarrhea Treatment Market
Market Size Estimates: Antibiotic-associated diarrhea treatment market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Antibiotic-associated diarrhea treatment market size by route of administration, distribution channel, and region in terms of value ($B).
Regional Analysis: Antibiotic-associated diarrhea treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different route of administration, distribution channels, and regions for the antibiotic-associated diarrhea treatment market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antibiotic-associated diarrhea treatment market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for antibiotic-associated diarrhea treatment market?
Answer: The global antibiotic-associated diarrhea treatment market is expected to grow with a CAGR of 11.5% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the antibiotic-associated diarrhea treatment market?
Answer: The major drivers for this market are the increasing use of antibiotics, the rising awareness of gut health, and the growing prevalence of gastrointestinal disorders.
Q3. What are the major segments for antibiotic-associated diarrhea treatment market?
Answer: The future of the antibiotic-associated diarrhea treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, drug store, and online pharmacy markets.
Q4. Who are the key antibiotic-associated diarrhea treatment market companies?
Answer: Some of the key antibiotic-associated diarrhea treatment companies are as follows:
• Merck & Co
• TECHLAB
• Manav Drugs
• Pfizer
• Aurobindo Pharma
• CutisPharma
• Cosmo Pharmaceuticals
Q5. Which antibiotic-associated diarrhea treatment market segment will be the largest in future?
Answer: Lucintel forecasts that, within the route of administration category, oral is expected to witness higher growth over the forecast period.
Q6. In antibiotic-associated diarrhea treatment market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the antibiotic-associated diarrhea treatment market by route of administration (oral and injectable), distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Antibiotic-Associated Diarrhea Treatment Market, Antibiotic-Associated Diarrhea Treatment Market Size, Antibiotic-Associated Diarrhea Treatment Market Growth, Antibiotic-Associated Diarrhea Treatment Market Analysis, Antibiotic-Associated Diarrhea Treatment Market Report, Antibiotic-Associated Diarrhea Treatment Market Share, Antibiotic-Associated Diarrhea Treatment Market Trends, Antibiotic-Associated Diarrhea Treatment Market Forecast, Antibiotic-Associated Diarrhea Treatment Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.